EpiEndo
Desconocido
BRONCHOTHELIN: The first in class disease modifying drug for chronic airway disorders
EpiEndo Pharmaceuticals ehf
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
EpiEndo Pharmaceuticals is a drug development company focused on developing novel drugs that target epithelial differentiation and enhance r...
2020-05-06 - 2021-12-31 | Financiado
2020-05-06 - 2021-12-31 | Financiado
Bronchomycn: First in class epithelial Barrier enhancing medicine for respiratory diseases
EpiEndo Pharmaceuticals ehf
tramitó un
H2020:
H2020-SMEInst-2016-2017
Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there...
2017-01-26 - 2017-05-31 | Financiado
2017-01-26 - 2017-05-31 | Financiado
* No se disponen de datos de la empresa actual.